Loke, JustinUpasani, VinitGaskell, CharlotteFox, SoniaFletcher, RachelThomas, CatherineHopkins, LouiseKumari, AnitaTang, TinaYafai, EmilyBoucher, RebeccaHomer, VictoriaToth, ArpadChan, Y L TraceyRandall, KatieRider, TomO'Nions, JennyDrew, VictoriaPillai, ArvindDungarwalla, MoezMurray, DuncanKhan, AnjumWandroo, FarooqMoore, SallyKrishnamurthy, PramilaHuang, Ya-Wen JessicaKnapper, SteveByrne, JennyZhao, RuiCraddock, CharlesParry, HelenMoss, PaulStanworth, Simon JLowe, David MMurray, Duncan2023-08-172023-08-172023-06-12Br J Haematol . 2023 Aug;202(3):498-5031365-214110.1111/bjh.1889437303189http://hdl.handle.net/20.500.14200/1714Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.en© 2023 British Society for Haematology and John Wiley & Sons Ltd.HaematologyArticle